Daewoong Pharma (069620) - Total Assets
Based on the latest financial reports, Daewoong Pharma (069620) holds total assets worth ₩2.26 Trillion KRW (≈ $1.53 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Daewoong Pharma debt service capacity to assess how comfortably operating cash covers total debt obligations.
Daewoong Pharma - Total Assets Trend (2007–2024)
This chart illustrates how Daewoong Pharma's total assets have evolved over time, based on quarterly financial data. See Daewoong Pharma (069620) shareholders funds for net asset value and shareholders' equity analysis.
Daewoong Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Daewoong Pharma's total assets of ₩2.26 Trillion consist of 31.0% current assets and 69.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.2% |
| Accounts Receivable | ₩160.74 Billion | 8.1% |
| Inventory | ₩256.35 Billion | 13.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩285.86 Billion | 14.5% |
| Goodwill | ₩60.85 Billion | 3.1% |
Asset Composition Trend (2007–2024)
This chart illustrates how Daewoong Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Daewoong Pharma.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daewoong Pharma's current assets represent 31.0% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2024, down from 7.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 14.5% of total assets.
Daewoong Pharma Competitors by Total Assets
Key competitors of Daewoong Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Daewoong Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.07 | 1.62 |
| Quick Ratio | 0.70 | 0.61 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩105.61 Billion | ₩36.10 Billion | ₩201.60 Billion |
Daewoong Pharma - Advanced Valuation Insights
This section examines the relationship between Daewoong Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.28 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 26.3% |
| Total Assets | ₩1.98 Trillion |
| Market Capitalization | $887.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daewoong Pharma's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daewoong Pharma's assets grew by 26.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daewoong Pharma (2007–2024)
The table below shows the annual total assets of Daewoong Pharma from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.98 Trillion ≈ $1.34 Billion |
+26.26% |
| 2023-12-31 | ₩1.57 Trillion ≈ $1.06 Billion |
+0.15% |
| 2022-12-31 | ₩1.56 Trillion ≈ $1.06 Billion |
+10.47% |
| 2021-12-31 | ₩1.42 Trillion ≈ $959.05 Million |
+3.53% |
| 2020-12-31 | ₩1.37 Trillion ≈ $926.33 Million |
+9.73% |
| 2019-12-31 | ₩1.25 Trillion ≈ $844.17 Million |
+3.13% |
| 2018-12-31 | ₩1.21 Trillion ≈ $818.54 Million |
-0.47% |
| 2017-12-31 | ₩1.21 Trillion ≈ $822.39 Million |
+6.01% |
| 2016-12-31 | ₩1.14 Trillion ≈ $775.75 Million |
+21.19% |
| 2015-12-31 | ₩944.53 Billion ≈ $640.09 Million |
+36.05% |
| 2014-12-31 | ₩694.26 Billion ≈ $470.49 Million |
+19.90% |
| 2013-12-31 | ₩579.01 Billion ≈ $392.39 Million |
+20.04% |
| 2012-12-31 | ₩482.34 Billion ≈ $326.88 Million |
-3.23% |
| 2011-12-31 | ₩498.46 Billion ≈ $337.80 Million |
+2.51% |
| 2008-12-31 | ₩486.24 Billion ≈ $329.52 Million |
+23.79% |
| 2007-12-31 | ₩392.81 Billion ≈ $266.20 Million |
-- |
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more